Robert Matson

Mr. Robert Matson

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2024 in npj Systems Biology and Applications
Verified
Journal Article
Open access
PDF file
RMRobert Matson
Robert Matson
ICIsin Y. Comba
Isin Y. Comba
ESEli Silvert
Eli Silvert
MNMichiel J. M. Niesen
Michiel J. M. Niesen
KMKarthik Murugadoss
Karthik Murugadoss
VSVenky Soundararajan
Venky Soundararajan
Understanding which viral variants evade neutralization is crucial for improving antibody-based treatments, especially with rapidly evolving viruses like SARS-CoV-2. Yet, conventional assays are labor intensive and cannot capture the full spectrum of variants. We present a deep learning approach to predict changes in neutralizing antibody activity of COVID-19 therapeutics and vaccine-elicited sera/plasma against emerging viral variants. Our approach leverages data of 67,885 unique SARS-CoV-2 Spike sequences and 7,069 in vitro assays. The resulting model accurately predicted fold changes in neutralizing activity (R2 = 0.77) for a test set (N = 980) of data collected up to eight months after the training data. Next, the model was used to predict changes in activity of current therapeutic and vaccine-induced antibodies against emerging SARS-CoV-2 lineages. Consistent with other work, we found significantly reduced activity against newer XBB descendants, notably EG.5, FL.1.5.1, and XBB.1.16; primarily attributed to the F456L spike mutation.

9 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
RMRobert Matson
Robert Matson
KMKarthik Murugadoss
Karthik Murugadoss
AVAj Venkatakrishnan
Aj Venkatakrishnan
VSVenky Soundararajan
Venky Soundararajan
Semaglutide and tirzepatide are not approved for type 1 diabetes, and their real-world associations with insulin requirements, metabolic outcomes, and safety remain uncertain. Here we analyzed de-identified federated U.S. EHR data, comparing adults with T1D initiating semaglutide (n=1,424) or tirzepatide (n=578) between Jan 1, 2018, and Dec 31, 2025, with 1:1 propensity-score matched T1D controls without GLP-1RA/tirzepatide exposure (n=2,002). At 12 months mean insulin total daily dose (TDD) percent change was −22.0% (median −9.3%) in the semaglutide subcohort and −19.7% (median −17.2%) in the tirzepatide subcohort versus +10.3% (median +0.4%) in matched controls, widening to −27.4% (median −19.4%) and −25.9% (median −31.5%) versus +10.4% (median −1.1%) in controls at 24 months (all P<0.0001). The rate of patients achieving a ≥10% TDD reduction at 6 months was 51.0% (semaglutide) and 50.3% (tirzepatide) versus 18.4% in controls (both P<0.0001). At 12 months median semaglutide dose was 0.50 mg (Q1, Q3: 0.25, 1.00), with 67.8% of patients above the 0.25 mg starter dose. Median tirzepatide dose was 5.00 mg (Q1, Q3: 2.50, 7.50), with 68.2% of patients above the 2.5 mg starter dose. Stratified analysis of 12-month TDD percent change showed significant heterogeneity by weight-loss category in the semaglutide subcohort with mean TDD reduction of −34.5% in patients losing ≥10% of body weight versus −19.6% in patients with <5% weight loss (P<0.001); semaglutide dose escalation was also associated with mean TDD reduction (1.7–2.4 mg, −31.8%; 0.25 mg, −18.2%; P=0.007) while tirzepatide dose escalation was not significantly associated with TDD reduction (ANOVA P=0.800). At 12 months mean HbA1c percent change from baseline was −4.2% (semaglutide, P<0.0001) and −3.0% (tirzepatide, P=0.007) versus −0.3% in controls and mean body weight percent change was −4.0% and −6.8% versus −0.5% (both P<0.0001). The pre-versus-post 365-day safety profile across 13 prespecified events was gastrointestinal-predominant, with nausea or vomiting increasing by 8.5 percentage points (Benjamini-Hochberg adjusted P [BH P] 30% had significantly higher incidence of diabetic ketoacidosis (5.42 events per 100 person-years; BH P=0.034). Across 24 prespecified cardiovascular and renal time-to-event endpoints, exposure to semaglutide or tirzepatide was associated with lower 2-year all-cause mortality (1.4% versus 5.7%; BH P<0.001) and major adverse cardiovascular events (4.2% versus 7.5%; BH P=0.002), with mortality reductions for both drugs individually and a reduction in major adverse cardiovascular events for tirzepatide; no renal endpoint remained significant after multiple-testing correction. In summary, this study demonstrates real-world reductions in daily insulin requirements, HbA1c, and weight in T1D patients after initiation of semaglutide or tirzepatide, motivating prospective evaluation of these therapies as adjunctive therapy in selected T1D adults.

13 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AMAdhikaar Marwaha
Adhikaar Marwaha
AVAj Venkatakrishnan
Aj Venkatakrishnan
AAAvinash Aman
Avinash Aman
SSSanthosh Shivabasappa
Santhosh Shivabasappa
RMRobert Matson
Robert Matson
VSVenky Soundararajan
Venky Soundararajan
The U.S. Medicare GLP-1 Bridge program and existing Part D pathways are expanding access to tirzepatide therapy for older adults, including Zepbound through the Bridge for weight management and Mounjaro through Part D coverage for type 2 diabetes. This necessitates identification of clinical vulnerabilities in geriatric patients that may emerge during pharmacologic weight loss. Here we evaluated incident malnutrition, protein-energy malnutrition (PEM), appetite suppression, dehydration, and sarcopenia in the context of tirzepatide-associated weight loss among adults aged 65 years or older, and we quantified associated mortality, intensive care unit (ICU) admission, and hospitalization relative to comparator cohorts of patients who were prescribed other antidiabetic medications (metformin, DPP4 or SGLT2 inhibitors) or underwent bariatric surgery. Incident frailty-related phenotypes rose with larger achieved weight loss. Specifically, anorexia increased from 2.9% (at ≤5% weight loss) to 10.2% (at 30-40%); dehydration from 1.8% to 4.8%; malnutrition from 0.8% to 3.1%; and PEM from 0.5% to 2.9%. Median tirzepatide treatment duration increased from 1.2 months at ≤5% weight loss to 13.2 months at 30-40%, whereas duration was largely invariant by baseline BMI from 40. The development of frailty phenotypes after tirzepatide initiation was associated with increased rates of mortality (RR 25, 95% CI 18-35), ICU admission (RR 20, 95% CI 16-25), and hospitalization (RR 11, 95% CI 9.8-12) relative to tirzepatide-treated patients who did not develop malnutrition. Baseline features enriched among patients who developed frailty phenotypes after tirzepatide initiation were older age, advanced diabetes, pre-existing MAFLD/MASH, and cardiorenal comorbidities. Physician-reviewed cause-of-death among decedents with incident frailty phenotypes after tirzepatide initiation showed respiratory failure, septic shock, advanced malignancy, and multiorgan failure as leading causes of death. Overall, in this observational study of Medicare-age-eligible adults, incident frailty phenotyping during tirzepatide-associated weight loss identified vulnerable subgroups with baseline cardiometabolic burden, highlighting the need for comprehensive clinical decision support and multimodal patient monitoring with increasing weight-loss.

3 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AVAj Venkatakrishnan
Aj Venkatakrishnan
RMRobert Matson
Robert Matson
KMKarthik Murugadoss
Karthik Murugadoss
AAAvinash Aman
Avinash Aman
DADeepak Anand
Deepak Anand
VSVenky Soundararajan
Venky Soundararajan
Understanding organ-specific effects of multi-agonist metabolic therapies beyond weight loss remains challenging, particularly while randomized clinical trials are ongoing and treatment allocation remains blinded. Here, we evaluated whether real-world longitudinal biomarker trajectories can provide early hypothesis-generating signals associated with masked trial-medication exposure. Using propensity-matched, de-identified electronic health records from a large federated health network, we compared changes in laboratory and physiologic biomarkers across receptor-defined metabolic therapies. Semaglutide, tirzepatide, and pramlintide served as reference therapies representing GLP-1 receptor, dual GIPR-GLP1R, and amylin-pathway pharmacology, respectively. Individuals with documented participation in a blinded CagriSema/placebo clinical trial were analyzed as a single masked exposure group because active treatment assignment could not be determined from routine-care records. Twenty-five CagriSema/placebo participants were propensity matched 1:5 to tirzepatide (n=125) and empagliflozin (n=125). At 6 months, the masked CagriSema/placebo cohort showed similar changes in weight and HbA1c compared with matched tirzepatide-treated patients (weight, -7.7% vs -10.2%, P=0.27; HbA1c, -2.8% vs -5.1%, P=0.69), but larger increases in estimated glomerular filtration rate (+26.4% vs +6.5%, BH P=0.028). Compared with matched empagliflozin-treated patients, the masked cohort demonstrated larger reductions in weight (-7.7% vs -3.5%, P=0.048), mean arterial pressure (-12.0% vs -1.0%, BH P<0.001), creatinine (-17.4% vs -2.4%, BH P=0.020), and greater increases in eGFR (+26.4% vs +6.4%, BH P=0.030). To provide pharmacologic context, patients with type 2 diabetes receiving basal insulin who initiated pramlintide were independently matched to tirzepatide (652 pairs) and semaglutide (761 pairs). Tirzepatide and semaglutide were associated with larger HbA1c reductions than pramlintide at 6 months (-9.0% vs -3.0%, BH P<0.001; -10.1% vs -3.5%, BH P<0.001). However, after normalization for weight loss, pramlintide demonstrated greater blood pressure reduction per kilogram of weight lost than tirzepatide for both systolic (-4.9 vs -3.4% per kg, BH P=0.046) and diastolic blood pressure (-5.7 vs -3.4% per kg, BH P=0.029), whereas tirzepatide and semaglutide showed similar weight-normalized laboratory responses. Medication-transition analyses did not support co-intervention confounding, and single-cell transcriptomic analyses demonstrated substantially broader expression of amylin receptor components (CALCR, RAMP1/2/3) than GIPR or GLP1R in the kidney (9.8-14.7-fold). These findings illustrate how real-world longitudinal biomarker analyses can complement ongoing blinded clinical trials by identifying early, hypothesis-generating physiologic signals associated with masked trial-medication exposure. The observed renal and blood-pressure patterns, together with receptor-expression analyses, motivate prospective evaluation after trial unblinding to determine whether they reflect amylin-pathway biology or other treatment-associated effects.

9 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
RMRobert Matson
Robert Matson
AVAj Venkatakrishnan
Aj Venkatakrishnan
KMKarthik Murugadoss
Karthik Murugadoss
VSVenky Soundararajan
Venky Soundararajan
Respiratory viral infections continue to impose a large burden of hospitalization, organ failure and death, particularly among older adults and people with cardiometabolic disease. Whether prior semaglutide exposure is associated with lower post-infection severity across distinct respiratory viruses remains uncertain. We analyzed de-identified longitudinal electronic health record data from a federated U.S. network spanning more than 29 million patients. Adults with documented COVID-19 or influenza infection were classified by pre-infection semaglutide use versus no prior GLP-1 receptor agonist use and one-to-one propensity matched on demographics, BMI, HbA1c, vaccination status, prior infection status, antiviral use, healthcare utilization extent, several comorbidities, yielding matched cohorts of N=11,238 for COVID-19 and N=3,409 for influenza (flu). In the COVID-19 cohort, semaglutide exposure was associated with significantly lower (all P<0.001) 30-day mortality (0.1% vs 0.4%, RR 0.26), hospitalization (4.2% vs 7.2%, RR 0.58), ICU admission (1.0% vs 1.9%, RR 0.52), mechanical ventilation (0.4% vs 0.8%, RR 0.49), and the composite of all the outcomes listed (4.4% vs 7.7%, RR 0.57). In the flu cohort, semaglutide use was also associated (all P≤0.03) with significantly lower hospitalization (4.4% vs 7.8%, RR 0.57), ICU admissions (1.3% vs 1.9%, RR 0.67), mechanical ventilation (0.3% vs 0.6%, RR 0.43), and the composite outcome (4.5% vs 8.1%, RR 0.56). Significant risk reductions (all P<0.005) were also observed for acute coronary syndrome (COVID-19 RR 0.55; flu RR 0.42), acute respiratory failure (COVID-19 RR 0.63; flu RR 0.45), and acute kidney injury (COVID-19 RR 0.56; flu RR 0.54) in the 30-day observation period. Within the COVID-19 cohort, across both the full study period (vaccinated: RR, 0.54; unvaccinated: RR, 0.58) and specifically during the pandemic period ending May 11, 2023 (vaccinated: RR, 0.63; unvaccinated: RR, 0.59), prior semaglutide exposure was associated with significantly (p<0.01) and comparably lower composite COVID-19 severity, suggesting a public-health signal that may complement vaccination in documented recently vaccinated patients while also identifying a potentially scalable risk-reduction strategy for patients without documented recent vaccination. When restricting to those treated with standard-of-care therapeutics during the COVID-19 pandemic era, semaglutide users had significantly lower (p<0.05) 30-day composite risk among those on metformin (4.8% vs 7.6%; RR 0.64) and among those receiving Paxlovid ±7 days of infection (3.6% vs 10.1%; RR 0.35). Among those initiating corticosteroids ±7 days of infection, mortality and ICU admission were numerically lower but not statistically significant. Among the influenza cohort, semaglutide-associated composite risk reduction was comparable across vaccination strata (unvaccinated: RR, 0.56; vaccinated: RR, 0.59), suggesting a complementary public-health signal for reducing seasonal influenza severity both after documented vaccination and among patients without documented recent flu vaccination. Notably, semaglutide significantly reduced (P<0.01) composite risk even among adults aged ≥65 years for both COVID-19 (7.9% vs 11.8%; RR 0.67) and influenza (11.8% vs 16.2%; RR 0.73). Finally, composite risk did not vary significantly across pre-infection weight loss strata of <5%, 5–15%, and ≥15% for COVID (P=0.89) or flu (P=0.54), or across dosage strata of 0.25–0.5, 1.0, and 1.7–2.4 mg/week for COVID (P=0.50) or flu (P=0.32), suggesting semaglutide associated COVID and Flu protection may not require substantial weight loss or maximal dosing. Taken together with growing evidence of weight-loss-independent benefits of cardiovascular, renal, pulmonary and neurological systems, this study motivates prospective evaluation of low-dose semaglutide to blunt the severity of respiratory viral infections.

25 September 2026 in Diabetology
Verified
Journal Article
Open access
PDF file
RMRobert Matson
Robert Matson
KMKarthik Murugadoss
Karthik Murugadoss
AVAj Venkatakrishnan
Aj Venkatakrishnan
VSVenky Soundararajan
Venky Soundararajan
Background: Semaglutide and tirzepatide are not approved for type 1 diabetes (T1D), and their real-world effects on insulin requirements, metabolic outcomes, and safety are uncertain. Methods: Using de-identified electronic health record data from a federated U.S. network (2018–2025), adults with T1D who initiated semaglutide (n = 1447) or tirzepatide (n = 568) were matched 1:1 to unexposed adults with T1D on demographics, comorbidities, glycated hemoglobin (HbA1c), body mass index (BMI), estimated glomerular filtration rate (eGFR), T1D duration, healthcare utilization, and calendar year (Cohort A). Insulin total daily dose (TDD) was analyzed in a second cohort additionally matched on baseline TDD and insulin delivery modality (Cohort B; 337 semaglutide and 117 tirzepatide pairs). Results: At 12 months, TDD changed by −12.9% with semaglutide versus −2.6% in matched controls (difference −10.4 percentage points [pp]; p < 0.001) and by −10.4% with tirzepatide versus +13.3% (difference −23.7 pp; p = 0.02); a ≥10% TDD reduction was reached by 41% versus 21% of patients with semaglutide and 47% versus 11% with tirzepatide (both p < 0.001). Among semaglutide-treated patients, 6-month-TDD reduction was −24.1%, −12.6%, and −5.6% with ≥10% weight loss, 0 to <10% loss, and weight gain (p < 0.001), but did not vary with HbA1c change (p = 0.95) or semaglutide dose (p = 0.50). At 12 months, HbA1c fell 0.31 pp more with semaglutide than in controls (p < 0.001) and 0.19 pp more with tirzepatide (p = 0.07); body weight fell 3.3 pp and 5.1 pp more with semaglutide and tirzepatide, respectively (both p < 0.001). Relative to matched controls, the 365-day risk of nausea or vomiting rose 8.6 pp after semaglutide or tirzepatide initiation (p < 0.001) and constipation rose 3.4 pp (p = 0.003), whereas diabetic ketoacidosis (+0.3 pp; p = 0.63) and severe hypoglycemia (−0.8 pp; p = 0.39) did not change significantly. Conclusions: In routine care, adjunctive semaglutide and tirzepatide were associated with lower insulin requirements, modest HbA1c improvement, and weight loss in adults with T1D, with a gastrointestinal-predominant adverse-event profile. Randomized trials are needed to establish efficacy and safety.